An Overview of Seattle Genetics Inc.
Seattle Genetics is a great company that has its primary goal set on providing drugs that facilitate therapy to the cancer patients. Outside their building, you will see a symbol of a human antibody alluding to the rigorous research work they are engaged in, using the human antibody in pursuit of better health for the cancer patients.
Clay Siegall is the Chief Executive Officer, the chairman of the board and the president of the Seattle Genetics Inc. that provides cancer therapy. The organization is said to offer twelve cancer therapy drugs and one approved medication product called Adcentris.
According to Doctor Clay, the drugs offered by his company stand out above others in the industry because of the formulation and how these drugs work. The standard cancer treatment aims at the destruction of all the dividing cells whether bad or good, or healthy or unhealthy cells. Such, a scenario is not good because the healthy and good cells should be preserved. He states that at Seattle Genetics the approach is different. The therapies are subdivided into three treatments. One focuses on the immune system, the second on the outside of the cell and the final inside the cell. With such determined and individual treatments, the healthy ones are spared the harm. And that remains the heart and objective of the Seattle Inc., to keep researching and offering evidence based cancer treatments.
The Person Clay Siegall
Clay’s love for research and evidence based treatment originated from his teenage experience when his father was diagnosed with brain cancer. At nineteen, he would sometimes accompany his father to oncologist where he would gain an opportunity to ask some questions about cancer therapies and treatment. His inquisitive nature and desire to see health restored among cancer patients became his motivation to pursue medicine and research.
Clay Siegall is a Ph.D. holder of George Washington University. This university works in close collaboration with National Institute of Health (NIH) where he did his internship. Furthermore, he had an opportunity for a two-year’ doctoral fellowship at NIH in a full-time position. It is while there that he got the chance to publish his research papers related to cancer research. Notably, he remained focused on cancer therapies, and none of the pharmaceutical companies whose focus is not cancer treatment would derail him from his goals through offering him a job.